CAS: 1800487-55-1; N-(3-(1H-Pyrazol-4-yl)Propyl)-3-((4-Fluorophenyl)Ethynyl)-4-(Pyridin-4-yl)Benzamide

主要参考文献

1: Messana VG, Fascì A, Vitale N, Micillo M, Rovere M, Pesce NA, Martines C, Efremov DG, Vaisitti T, Deaglio S. A molecular circuit linking the BCR to the NAD biosynthetic enzyme NAMPT is an actionable target in Richter syndrome. Blood Adv. 2024 Apr 23;8(8):1920-1933. doi: 10.1182/bloodadvances.2023011690.
2: McKay-Corkum GB, Collins VJ, Yeung C, Ito T, Issaq SH, Holland D, Vulikh K, Zhang Y, Lee U, Lei H, Mendoza A, Shern JF, Yohe ME, Yamamoto K, Wilson K, Ji J, Karim BO, Thomas CJ, Krishna MC, Neckers LM, Heske CM. Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models. Clin Cancer Res. 2023 Nov 1;29(21):4479-4491. doi: 10.1158/1078-0432.CCR-23-0200.
3: Wei Y, Xiang H, Zhang W. Review of various NAMPT inhibitors for the treatment of cancer. Front Pharmacol. 2022 Sep 7;13:970553. doi: 10.3389/fphar.2022.970553.

合成参考文献

参考文献:10.1038/s41375-019-0692-5
摘要:Korotchkina L, Kazyulkin D, Komarov PG, Polinsky A, Andrianova EL, Joshi S, Gupta M, Vujcic S, Kononov E, Toshkov I, Tian Y, Krasnov P, Chernov MV, Veith J, Antoch MP, Middlemiss S, Somers K, Lock RB, Norris MD, Henderson MJ, Haber M, Chernova OB, Gudkov AV. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020 Jan 02;34(7):1828–39. doi: 10.1038/s41375-019-0692-5.